Tissue Factor and Factor VIIa Complex Inhibitors in Cardiovascular Disease
Author Information
Author(s): Petrillo Gianluca, Cirillo Plinio, D’Ascoli Greta-Luana, Maresca Fabio, Ziviello Francesca, Chiariello Massimo
Primary Institution: University of Naples 'Federico II'
Hypothesis
Can inhibitors of the Tissue Factor/Factor VIIa complex provide therapeutic benefits in cardiovascular disease?
Conclusion
Inhibitors of the TF/VIIa complex may offer significant advantages in preventing thrombus formation in cardiovascular disease.
Supporting Evidence
- TF plays a pivotal role in the pathophysiology of acute coronary syndromes.
- Recombinant human TFPI has shown promise in preventing thrombus formation in experimental models.
- TF expression is linked to various inflammatory markers and cardiovascular disease.
- Plasma TF activity may predict atherothrombotic risk in patients with acute coronary syndromes.
Takeaway
This study looks at how certain proteins in the blood can cause heart problems and how blocking them might help treat those issues.
Methodology
The report reviews recent advances in the field of inhibitors of the TF/VIIa complex and their potential use in cardiovascular disease.
Limitations
Ethical concerns regarding the systemic administration of TFPI due to increased bleeding risks.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website